コンテンツへスキップ
Merck
  • Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture.

Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture.

Journal of plastic surgery and hand surgery (2012-06-08)
Chris Bainbridge, Robert A Gerber, Piotr P Szczypa, Ted Smith, Harvey Kushner, Brian Cohen, Marie-Pierre Hellio Le Graverand-Gastineau
要旨

Collagenase Clostridium histolyticum (CCH) is a non-surgical, efficacious therapy for Dupuytren's contracture (DC). This study evaluated the efficacy and safety of CCH in patients with previous DC surgery. Data from 12 CCH clinical trials were pooled. At screening, patients provided details about the type/date of previous DC surgery. Reviewers coded descriptions to the Operated Hand, finger, and joint. Of 1082 patients, 422 (39%) had previous DC surgery. For these patients with previous surgery, the CCH treatment was coded on the Operated (n = 206) or Non-operated Hand (n = 196). End-points included changes in fixed-flexion contracture (FFC) and range of motion (ROM). Adverse events (AEs) were monitored. After treatment with CCH, FFC at metacarpophalangeal joints was reduced by 75% in previously Operated Hands and by 80% for Non-operated Hands (p = 0.6). Improvements in ROM were 32° and 32°, respectively (p = 0.9). For proximal inter-phalangeal joints, the reductions in FFC for the Operated and Non-operated Hands were 52% and 50%, respectively (p = 0.6); improvements in ROM were 24° and 26°, respectively (p = 0.3). Some AE rates were significantly higher in the Operated vs Non-operated Hand groups, but were not clinically relevant. There were no between-group significant differences in AE duration (p > 0.08). Previous surgery for DC does not affect efficacy or safety of CCH, suggesting CCH is an option in patients with recurring DC. Some AE rates were significantly higher, but not clinically relevant.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, suitable for release of physiologically active rat hepatocytes, Type IV, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, for general use, Type I, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, suitable for release of physiologically active rat epididymal adipocytes, Type II, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, Type IA, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid, For general use
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, suitable for release of rat epididymal adipocytes and hepatocytes (for methodology see Type II and Type IV), Type VIII, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, Type XI, 2-5 FALGPA units/mg solid, ≥800 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, Type V, ≥1 FALGPA units/mg solid, >125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, lyophilized powder, ≥125 CDU/mg solid (CDU = collagen digestion units), 0.5-5.0 FALGPA units/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, powder, Suitable for the digestion and isolation of physiologically active pancreatic islet cells, suitable for cell culture
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, 0.2 μm filtered, high purity, purified by chromatography, Type VII-S, ≥4 FALGPA units/mg solid, ≥700 CDU/mg solid (CDU = collagen digestion units)
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, lyophilized powder (from 0.2μm filtered solution), 0.5-5.0 FALGPA units/mg solid, suitable for cell culture
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, 0.2 μm filtered, suitable for release of physiologically active rat hepatocytes, Type IV-S, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, high purity, purified by chromatography, Type VII, ≥4 FALGPA units/mg solid, lyophilized powder, ≥700 CDU/mg solid (CDU = collagen digestion units)
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, lyophilized powder (from 0.2 μm filtered solution), suitable for cell culture
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, 0.2 μm filtered, for general use, Type I-S, 0.2-1.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, powder, suitable for cell culture, ≥4 FALGPA units/mg solid, high purity, ≥700 CDU/mg solid (CDU = collagen digestion units)
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, 0.2 μm filtered, suitable for release of physiologically active rat epididymal adipocytes, Type II-S, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, Sigma Blend Type H, ≥1.0 FALGPA units/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, non-sterile; 0.2 μm filtered, Type IA-S, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, Sigma Blend Type F, ≥2.0 FALGPA units/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, purified by chromatography, ≥500 CDU/mg solid (CDU = collagen digestion units), lyophilized powder
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, 0.2 μm filtered, Type V-S, ≥1 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
コラゲナーゼ Clostridium histolyticum由来, Sigma Blend Type L, ≤1.0 FALGPA units/mg solid